Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Viracta Therapeutics Gets FDA Orphan Drug Designation for Nana-val

11/29/2021 | 08:35am EST

By Michael Dabaie

Viracta Therapeutics Inc. said the U.S. Food and Drug Administration granted its product candidate nanatinostat and valganciclovir, or Nana-val, orphan drug designation for the treatment of Epstein Barr virus-positive diffuse large B-cell lymphoma.

DLBCL is the most common subtype of non-Hodgkin lymphoma in the U.S. and worldwide, the company said.

Viracta shares rose 9.5% to $5.30 in premarket trading.

This is the fourth U.S. FDA orphan drug designation granted for Nana-val. Viracta has previously received FDA orphan drug designation for the treatment of T-cell lymphoma, post-transplant lymphoproliferative disorder and plasmablastic lymphoma.

The FDA grants orphan drug designations to investigational drugs and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

11-29-21 0835ET

All news about VIRACTA THERAPEUTICS, INC.
01/04Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
PR
2021VIRACTA THERAPEUTICS, INC.(NASDAQGS : VIRX) added to NASDAQ Biotechnology Index
CI
2021Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index
PR
2021Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presenta..
CI
2021Viracta Says Epstein-Barr Therapy Had 40% Overall Response Rate in Trial; Shares Fall
MT
2021Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Sign..
CI
2021INSIDER SELL : Viracta Therapeutics
MT
2021Viracta Therapeutics Secures FDA Orphan Drug Designation for Lymphoma Combo Therapy
MT
2021Viracta Therapeutics Gets FDA Orphan Drug Designation for Nana-val
DJ
2021Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral ..
PR
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Capitalization 112 M 112 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 24
Free-Float 85,2%
Chart VIRACTA THERAPEUTICS, INC.
Duration : Period :
Viracta Therapeutics, Inc. Technical Analysis Chart | VIRX | US92765F1084 | MarketScreener
Technical analysis trends VIRACTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,00 $
Average target price 33,50 $
Spread / Average Target 1 017%
EPS Revisions
Managers and Directors
Ivor Royston Director
Daniel R. Chevallard Secretary, Chief Operating & Financial Officer
Roger J. Pomerantz Director
Lisa Rojkjaer Chief Medical Officer
Ayman El-Guindy Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VIRACTA THERAPEUTICS, INC.-17.81%112
MODERNA, INC.-26.53%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707